Abdominal Aortic Aneurysm (AAA) Trends

• AAA affects approximately 1–5% of adults over 65 years of age, with prevalence varying by age, sex, smoking history, and geographic region. The disease is significantly more common in men than women and is strongly associated with smoking and cardiovascular risk factors.
• Smoking remains the single most important modifiable risk factor and is associated with both aneurysm formation and accelerated aneurysm growth.
• The United States is expected to account for the largest share of the diagnosed AAA population across the 7MM during the forecast period, supported by its large elderly population, widespread access to diagnostic imaging, established screening recommendations, and high prevalence of cardiovascular risk factors.
• Men aged 65 years and older are expected to represent the largest proportion of the AAA patient population, reflecting the strong association between age, sex, and aneurysm development. However, women with AAA often present at older ages and may experience higher rupture risks at smaller aneurysm diameters.
• The diagnosed AAA population is anticipated to increase steadily between 2022 and 2036 due to demographic aging, improved disease awareness, expanded screening initiatives, and growing utilization of advanced imaging modalities for cardiovascular assessment.
• Increasing adoption of ultrasound-based screening programs, computed tomography angiography (CTA), and advanced risk stratification approaches is expected to improve early diagnosis and patient monitoring, supporting timely intervention and reducing the incidence of aneurysm rupture and associated mortality.

Abdominal Aortic Aneurysm (AAA) Epidemiology Forecast in the United States

• 2025 Prevalent Cases of AAA: ~XXXX
• 2036 Prevalent Cases of AAA:  XXXX
• AAA Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Abdominal Aortic Aneurysm (AAA) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the AAA, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Abdominal Aortic Aneurysm (AAA) Understanding 

Abdominal Aortic Aneurysm (AAA) Overview and Diagnosis

AAA is a progressive vascular disorder characterized by localized dilation and weakening of the abdominal aorta, the largest artery in the body responsible for delivering oxygen-rich blood from the heart to the abdominal organs and lower extremities. AAA typically develops when structural components of the aortic wall gradually deteriorate due to a combination of aging, chronic inflammation, extracellular matrix degradation, genetic predisposition, and cardiovascular risk factors. The condition is most commonly observed in older adults, particularly men over 65 years of age, and is strongly associated with smoking, hypertension, atherosclerosis, dyslipidemia, and a family history of aneurysmal disease. Most AAAs remain asymptomatic during early stages and are frequently detected incidentally during imaging studies performed for unrelated conditions. However, as the aneurysm enlarges, the risk of rupture increases substantially, potentially resulting in catastrophic internal bleeding and high mortality. Currently, no approved pharmacological therapies have been shown to reliably halt aneurysm growth or prevent rupture, making surveillance and timely surgical intervention the primary management strategies. Treatment is generally recommended when the aneurysm reaches a diameter of 5.5 cm or demonstrates rapid expansion, with open surgical repair and endovascular aneurysm repair (EVAR) serving as the standard therapeutic approaches. 

Diagnosis of abdominal aortic aneurysm is primarily based on imaging studies that assess aortic diameter, aneurysm morphology, growth rate, and rupture risk. Abdominal ultrasound is the preferred first-line diagnostic and screening modality due to its high sensitivity, non-invasive nature, cost-effectiveness, and ability to accurately measure aneurysm size. Computed tomography angiography (CTA) is widely utilized for detailed anatomical assessment, procedural planning, and evaluation of aneurysm extent, while magnetic resonance angiography (MRA) may be used in selected patients requiring additional vascular characterization. Diagnosis is generally established when the abdominal aortic diameter exceeds 3.0 cm. Following diagnosis, regular imaging surveillance is performed to monitor aneurysm progression and determine the optimal timing for intervention. Clinical evaluation also includes assessment of cardiovascular risk factors, smoking history, family history of aneurysmal disease, and coexisting vascular conditions. Ongoing research is exploring the use of circulating biomarkers, genetic markers, and advanced imaging techniques to improve risk stratification, predict aneurysm growth, and identify patients at increased risk of rupture, potentially enabling more personalized disease management in the future.

Further details are provided in the report…

Abdominal Aortic Aneurysm (AAA) Epidemiology

Key Findings from AAA Epidemiological Analysis and Forecast 

• The total diagnosed prevalent population of AAA across the 7MM was estimated at approximately 1.64 million cases in 2025 and is anticipated to increase during the study period (2022–2036), driven by population aging and improved diagnosis rates.
• The United States accounted for the largest diagnosed prevalent AAA population among the 7MM, with approximately 750,000 cases in 2025, reflecting its large elderly population and widespread use of diagnostic imaging.
• Among the EU4 and the UK, Germany represented the highest prevalent AAA population, followed by France, while Italy accounted for the lowest number of prevalent cases.
• In Japan, approximately 181,000 males and 72,000 females were affected by AAA in 2025. The overall prevalence in Japan is expected to decline gradually during the forecast period due to demographic changes and declining smoking rates.
• The total prevalent AAA population in Japan was approximately 250,000 cases, and epidemiological projections suggest a gradual decrease through 2036.
• In the United States, AAA remains considerably more common in men, with nearly 500,000 affected males and over 200,000 affected females, reflecting the strong gender disparity observed in the disease.
• In the United States, small AAAs (3.0–4.4 cm) represented the vast majority of diagnosed cases, accounting for approximately 700,000 patients in 2025. Medium-sized AAAs (4.5–5.4 cm) accounted for approximately 60,000 cases, while large AAAs (≥5.5 cm) represented only a small proportion of the total patient population.
• The total treatable population of AAA in the United States was approximately 560,000 cases in 2025 and is expected to increase steadily throughout the forecast period, reaching approximately 740,000 cases by 2036.

Scope of the Report

The report covers a segment of an executive summary, a descriptive overview of AAA, explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Abdominal Aortic Aneurysm Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Abdominal Aortic Aneurysm (AAA)? What will be the growth opportunities across the 7MM concerning the patient population with Abdominal Aortic Aneurysm (AAA) ?
  
• What is the historical and forecasted Abdominal Aortic Aneurysm (AAA) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.